Familial Pancreatic Cancer (FPC) accounts for an estimated 5-10% of all pancreatic cancer and is one area of hope in this otherwise highly lethal malignancy. In this proposal, we plan to identify the mutant gene that was inherited in patients using a series of new pancreatic cancer cell lines from patients in families with multiple pancreatic cancers. We will use the same approach and team that recently identified another gene (Palb2) that causes the disease. Once we find additional genes in Specific Aim 1, we will determine their prevalence in 96 additional affected families in Specific Aim 2. The work has important implications for: early detection, genetic counseling and possibly treatment, as follows: Once the gene is known, we will be able to identify which family members need aggressive surveillance for early detection and which have only population risk. Additionally, we will be able to counsel families about their risk of transmitting the disease to their offspring. Finally, one known cause of familial pancreatic cancer is germline BRCA2 gene defects and these cancers are uniquely sensitive to parp inhibitors. It is possible that any new defect will cause similar defects in double strand break repair or will be synthetic lethal with an existing chemotherapeutic drug. Hypothesis: FPC germline predisposition mutations explain the majority of FPC.
Specific Aim 1 : Perform whole-genome sequencing of 9 novel FPC cell lines and germline DNA. Analyze and assemble a list of candidate familial predisposition genes.
Specific Aim 2 : Confirm and determine the initial prevalence of the predisposition gene in germline samples from 96 additional patients with FPC.

Public Health Relevance

In 2010, more than 95% of pancreatic cancer patients will die of the disease within 5 years. One shining light is the potential to target patient's cancers that arose in a family cancer setting because they bear two defective copies of a DNA repair gene, an Achilles'heel. In this proposal we plan to discover all genes that cause familial pancreatic cancer and determine their prevalence.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21CA164592-02
Application #
8427329
Study Section
Cancer Genetics Study Section (CG)
Program Officer
Li, Jerry
Project Start
2012-02-15
Project End
2015-01-31
Budget Start
2013-02-01
Budget End
2015-01-31
Support Year
2
Fiscal Year
2013
Total Cost
$165,605
Indirect Cost
$63,380
Name
Johns Hopkins University
Department
None
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Lin, Ming-Tseh; Mosier, Stacy L; Thiess, Michele et al. (2014) Clinical validation of KRAS, BRAF, and EGFR mutation detection using next-generation sequencing. Am J Clin Pathol 141:856-66
McCall, Chad M; Mosier, Stacy; Thiess, Michele et al. (2014) False positives in multiplex PCR-based next-generation sequencing have unique signatures. J Mol Diagn 16:541-9
Chen, Guoli; Mosier, Stacy; Gocke, Christopher D et al. (2014) Cytosine deamination is a major cause of baseline noise in next-generation sequencing. Mol Diagn Ther 18:587-93